(NASDAQ: ANAB) Anaptysbio's forecast annual revenue growth rate of 2.98% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Anaptysbio's revenue in 2025 is $91,280,000.On average, 6 Wall Street analysts forecast ANAB's revenue for 2025 to be $1,648,431,479, with the lowest ANAB revenue forecast at $368,001,372, and the highest ANAB revenue forecast at $2,993,077,826. On average, 5 Wall Street analysts forecast ANAB's revenue for 2026 to be $3,022,579,269, with the lowest ANAB revenue forecast at $368,001,372, and the highest ANAB revenue forecast at $6,072,022,638.
In 2027, ANAB is forecast to generate $2,710,330,105 in revenue, with the lowest revenue forecast at $1,748,619,853 and the highest revenue forecast at $3,925,347,968.